Britannia Life Sciences Inc (BLAB) AI Stock Analysis

• Market Cap: C$17.04M
• Dividend Yield: N/A
• Average Volume (3M): 73.07K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.52
• Revenue Growth: -3.93%
• EPS Growth: -575.24%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.07
• Shares Outstanding: 162,254,330
• 10 Day Avg. Volume: 81,691
• 30 Day Avg. Volume: 73,070
• PEG Ratio: -0.81
• Price to Book (P/B): 1.93
• Price to Sales (P/S): 32.95
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: C$0.10 ▲(23.75% Upside)
• Action: Reiterated Date: 12/11/25
• Date: Action: Reiterated 12/11/25

The overall stock score is primarily influenced by the company's volatile financial performance and weak valuation. Technical analysis provides a slightly more positive outlook, but the lack of profitability and financial stability are significant concerns.

Positive Factors

Revenue Growth

Sustained triple-digit top-line growth demonstrates strong market traction and demand for the company’s offerings. Over a multi-month horizon this scale can enable operating leverage, support reinvestment in R&D or commercialization, and improve long-term competitiveness if growth persists.

Leverage Management

A trend of improving debt-to-equity reduces financial risk and interest burden, enhancing flexibility to fund strategic initiatives. Over months this durable improvement can lower refinancing risk, enable opportunistic investment or M&A, and strengthen resilience to industry cycles.

Free Cash Flow Efficiency

Positive free cash flow growth and strong FCF-to-income conversion indicate improving ability to turn earnings into cash. This durable cash generation can fund operations, reduce reliance on external capital, and support strategic spending or deleveraging over a 2–6 month horizon.

Negative Factors

Profitability Volatility

Persistently negative or volatile profitability undermines the company’s capacity to self-fund growth and erodes investor confidence. Over several months, margin instability makes planning and capital allocation difficult, increasing dependence on external financing and heightening execution risk.

Negative Operating Cash Flow

Negative operating cash flow signals the core business is not consistently generating cash from operations. This structural weakness forces reliance on financing or non-operating cash sources, which can strain liquidity and constrain investment or R&D over the medium term.

Low Equity Ratio

A low equity ratio and history of high leverage leave the firm more vulnerable to shocks and increase the cost of capital. Over a 2–6 month timeframe this structural fragility can limit strategic options, raise refinancing risk, and reduce ability to weather sector downturns.

Britannia Life Sciences Inc Business Overview & Revenue Model

Company Description

Britannia Life Sciences Inc. provides product testing, safety assessment, and compliance services to the cosmetics, nutraceutical, and consumer packaged goods industries in the United Kingdom and internationally. The company is based in Toronto, Canada.

How the Company Makes Money

Britannia Life Sciences Inc generates revenue through multiple streams, primarily from the sale of proprietary diagnostic products, licensing agreements for its patented technologies, and collaborations with pharmaceutical companies for drug development. The company also earns income from research grants and funding, as well as strategic partnerships that enhance its product offerings and market reach. Significant collaborations with health institutions and industry partners further bolster its revenue by providing access to broader markets and shared resources.

Britannia Life Sciences Inc Financial Statement Overview

Summary

Britannia Life Sciences Inc. shows strong revenue growth but struggles with profitability. The balance sheet indicates improved leverage management, yet financial instability remains a concern. Cash flow trends are mixed, with positive free cash flow growth but negative operating cash flow.

Income Statement

The income statement reveals significant volatility. While there is a remarkable revenue growth rate of 142.16% in the TTM, the company struggles with profitability, as indicated by negative net profit margins and fluctuating EBIT and EBITDA margins. The gross profit margin is high, but the net income is inconsistent, reflecting operational challenges.

Balance Sheet

The balance sheet shows a mixed picture. The debt-to-equity ratio has improved over time, indicating better leverage management, but it remains a concern with historical high leverage. Return on equity is positive in the TTM, suggesting some profitability, but the equity ratio is low, indicating potential financial instability.

Cash Flow

Cash flow analysis indicates some positive trends, with a recent increase in free cash flow growth. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is concerning. The free cash flow to net income ratio is above 1, suggesting some efficiency in converting income to cash.

Breakdown	TTM	Mar 2025	Jun 2023	Jun 2022	Mar 2022	Mar 2021
Income Statement
Total Revenue	-2.97M	369.28K	7.57M	6.40M	7.30M	1.42M
Gross Profit	-2.33M	27.33K	4.85M	4.64M	5.26M	1.17M
EBITDA	-4.56M	-4.39M	-1.90M	6.95M	-10.77M	-1.62M
Net Income	8.22M	7.39M	-4.77M	5.08M	-15.46M	-157.16K
Balance Sheet
Total Assets	10.31M	11.61M	22.26M	23.55M	21.09M	21.45M
Cash, Cash Equivalents and Short-Term Investments	861.63K	7.85M	1.32M	2.60M	1.63M	828.32K
Total Debt	2.44M	1.86M	7.29M	8.41M	5.19M	10.55M
Total Liabilities	5.26M	5.31M	15.59M	12.49M	15.61M	18.79M
Stockholders Equity	5.05M	6.30M	2.44M	7.02M	1.35M	-202.32K
Cash Flow
Free Cash Flow	-4.50M	-2.62M	1.75M	874.41K	2.71M	-543.49K
Operating Cash Flow	-4.40M	-2.62M	2.09M	1.22M	2.80M	-586.58K
Investing Cash Flow	6.20M	11.27M	-1.44M	-3.32M	653.95K	-4.91M
Financing Cash Flow	-1.91M	-2.17M	-1.97M	2.95M	-2.58M	6.20M

Britannia Life Sciences Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Positive. The current price of 0.08 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.09, and below the 200-day MA of 0.08, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 72.58 is Negative, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:BLAB.

Britannia Life Sciences Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$17.04M	-2.10	―	―	-3.93%	-575.24%
HEM	44 Neutral	C$15.62M	-2.75	―	―	―	-24.89%
GLOW	41 Neutral	C$9.06M	-3.68	-153.85%	―	239.98%	39.01%